Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Avistone Biotechnology Co., Ltd.
Summary
This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.
Official title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2025-03-06
Completion Date
2029-03-30
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
ANS03
ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).
Locations (5)
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Research Site
Fuzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Chengdu, Sichuan, China